Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed through a tissue biopsy.
- People who have had a CT scan or MRI showing the pancreatic cancer measures at least 1 cm at its widest point.
- People whose general health and ability to carry out daily activities falls within a certain range, rated 0 to 2 on a standard medical scale (confirm with trial site).
- People whose cancer is locally advanced, meaning it has not spread to distant parts of the body, has not responded to or has worsened during first-line chemotherapy, and has been assessed by a specialist team as not suitable for surgery.
- People whose tumour measures between 1 cm and 4 cm at its widest point.
Who may not be able to join:
- People whose cancer has spread to distant parts of the body.
- People whose tumour cannot be reached using an endoscope (a thin flexible camera inserted through the mouth).
- People who are pregnant.
- People who are unable to give informed consent to participate in the trial.
- People whose tumour is smaller than 1 cm or larger than 4 cm at its widest point.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tamas A. Gonda, MD, NYU Langone Health
Phone: 212-263-3095
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.